Drugs missing an ATC code

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. , the first Phase III clinical trial has been completed.

O-823 is a drug which is a cannabinoid derivative that is used in scientific research. It is described as a mixed agonist/antagonist at the cannabinoid receptor CB1, meaning that it acts as an antagonist when co-administered alongside a more potent CB1 agonist, but exhibits weak partial agonist effects when administered by itself.

JWH-147 is an analgesic drug used in scientific research, which acts as a cannabinoid agonist at both the CB1 and CB2 receptors. It is somewhat selective for the CB2 subtype, with a Ki of 11.0 nM at CB1 vs 7.1 nM at CB2. It was discovered and named after the renowned professor of organic chemistry John W. Huffman.

Selfotel (CGS-19755) is a drug which acts as a competitive NMDA antagonist, directly competing with glutamate for binding to the receptor. Initial studies showed it to have anticonvulsant, anxiolytic, analgesic and neuroprotective effects, and it was originally researched for the treatment of stroke, but subsequent animal and human studies showed phencyclidine-like effects, as well as limited efficacy and evidence for possible neurotoxicity under some conditions, and so clinical development was ultimately discontinued.

Oxaprotiline (developmental code name C 49-802 BDA), also known as hydroxymaprotiline, is a norepinephrine reuptake inhibitor belonging to the tetracyclic antidepressant (TeCA) family and is related to maprotiline. Though investigated as an antidepressant, it was never marketed.

2C-YN is an analog of phenethylamine that can be synthesized from 2C-I. Very little data exists about the pharmacological properties, metabolism, and toxicity of 2C-YN, although Daniel Trachsel lists it as having a dosage of around 50mg and a duration of around 2 hours, with relatively mild psychedelic effects.

LY-293284, also known as 4,α-methylene-5-acetyl-DPT, is a research chemical developed by the pharmaceutical company Eli Lilly and used for scientific studies. It acts as a potent and selective 5-HT1A receptor full agonist. It was derived through structural simplification of the ergoline based psychedelic LSD, but is far more selective for 5-HT1A with over 1000× selectivity over other serotonin receptor subtypes and other targets. It has anxiogenic effects in animal studies.

6-Diazo-5-oxo-L-norleucine (DON) is a glutamine antagonist, which was isolated originally from Streptomyces in a sample of Peruvian soil. This diazo compound is biosynthesized from lysine by three enzymes in bacteria. It is one of the most famous non-proteinogenic amino acid and was characterized in 1956 by Henry W Dion et al., who suggested a possible use in cancer therapy. This antitumoral efficacy was confirmed in different animal models. DON was tested as chemotherapeutic agent in different clinical studies, but was never approved. In 2019, DON was shown to kill tumor cells while reversing

Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter. It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.

APINACA (AKB48, '''N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide''') is a drug that acts as a reasonably potent agonist for the cannabinoid receptors. It is a full agonist at CB1 with an EC50 of 142 nM and Ki of 3.24 nM (compared to the Ki of Δ9-THC at 28.35 nM and JWH-018 at 9.62 nM), while at CB2 it acts as a partial agonist with an EC50 of 141 nM and Ki of 1.68 nM (compared to the Ki of Δ9-THC at 37.82 nM and JWH-018 at 8.55 nM). Its pharmacological characterization has also been reported in a discontinued patent application. It had never previously been reported in the scientific or p

'7,N,N-trimethyltryptamine (7,N,N-TMT or 7-TMT), also known as 7-methyl-DMT', is a serotonin receptor modulator and psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It was first described by 1978 and was encountered online as a novel designer drug in 2024.

Rilmazolam, is a benzodiazepine derivative which acts as a sedative and hypnotic drug, and the active metabolite of the drug Rilmazafone. It has never been developed for medical uses, yet the aforementioned prodrug is an approved medication in Japan. It is primarily metabolized to desmethylrilmazolam, di-desmethylrilmazolam, and carboxy rilmazolam

'''N-Ethyl-5-trifluoromethyl-2-aminoindane (ETAI''') is a drug of the 2-aminoindane family with putative entactogenic effects. It functions as a serotonin releasing agent (SRA). ETAI is the 2-aminoindane analogue of fenfluramine and has approximately 50% of the serotonergic neurotoxicity in comparison.

chemical compound

Isotonitazene is a synthetic opioid analgesic drug from the nitazene class and structural homolog of etonitazene, which has been sold as a designer drug. It has only around half the potency of etonitazene in animal studies, but it is likely even less potent in humans as was seen with etonitazene (1000 times as potent as morphine in animal models yet only 60 times as potent in humans). Isotonitazene (obtained from an online vendor) was fully characterized in November 2019 in a paper where the authors performed a full analytical structure elucidation in addition to determination of the potency a

Zelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan.

Vosilasarm, also known by the development codes RAD140 and EP0062 and by the black-market name Testolone or Testalone, is a selective androgen receptor modulator (SARM) which is under development for the treatment of hormone-sensitive breast cancer. It is specifically under development for the treatment of androgen receptor-positive, estrogen receptor-negative, HER2-negative advanced breast cancer. Vosilasarm was also previously under development for the treatment of sarcopenia (age-related muscle atrophy), osteoporosis, and weight loss due to cancer cachexia, but development for these indicat

Sibrafiban (Ro 48–3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients with acute coronary syndrome. The development of sibrafiban was terminated.

2-Fluorodeschloroketamine (also known as '''2'-Fl-2-Oxo-PCM, fluoroketamine, and 2-FDCK''') is a dissociative anesthetic related to ketamine. Its sale and use as a designer drug has been reported in various countries. It is an analogue of ketamine where the chlorine group has been replaced by fluorine. Due to its recent emergence, the pharmacological specifics of the compound are mostly unclear, but effects are reported to be similar to its parent compound, ketamine.

Pseudotropine (3β-tropanol, ψ-tropine, 3-pseudotropanol, or PTO) is a derivative of tropane and an isomer of tropine. Pseudotropine can be found in the Coca plant along with several other alkaloids ==Synthesis== In the laboratory it is made by the reduction of tropinone: According to the article, a good stereoselectivity of pseudotropine over endotropine could be achieved when employing a Meerwein–Ponndorf–Verley reduction or sodium metal in n-pentanol.

Tipiracil is a drug used in the treatment of cancer. It is approved for use in form of the combination drug trifluridine/tipiracil for the treatment of unresectable advanced or recurrent colorectal cancer.

ORG-26576 is an ampakine originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development. In animal studies it has been shown to effectively potentiate AMPA receptor function, leading to increased BDNF release and enhanced neuronal differentiation and survival, as well as producing nootropic effects in standardised assays. Development as an antidepressant has been halted due to a failed Phase II trial for major depressive disorder.

Fenticlor (also spelled fentichlor) is an antibacterial and antifungal agent for topical use. It is an antimicrobial agent. It is also used in veterinary medicine. __TOC__ ==Synthesis== It is prepared by the AlCl3-catalyzed reaction of 4-chlorophenol with sulfur dichloride. It can also be prepared by chlorination of bis[2-hydroxyphenyl]sulfide.

4-MeO-DMT, or 4-methoxy-DMT, also known as '4-methoxy-N,N-dimethyltryptamine or as O-methylpsilocin (PSOM'), is a serotonin receptor modulator and possible psychedelic drug of the tryptamine and 4-hydroxytryptamine families. It is the O-methylated analogue of psilocin (4-HO-DMT) and a positional isomer of 5-MeO-DMT.

A-84543 is a drug developed by Abbott, which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It is widely used in scientific research into the structure and function of this receptor subtype and has been the lead compound for the development of a large family of related derivatives.

Methoxphenidine (methoxydiphenidine, 2-MeO-Diphenidine, MXP) is a dissociative of the diarylethylamine class that has been sold online as a designer drug. Methoxphenidine was first reported in a 1989 patent where it was tested as a treatment for neurotoxic injury. Shortly after the 2013 UK ban on arylcyclohexylamines methoxphenidine and the related compound diphenidine became available on the gray market, where it has been encountered as a powder and in tablet form. Though diphenidine possesses higher affinity for the NMDA receptor, anecdotal reports suggest methoxphenidine has greater oral po

O-1918 is a synthetic compound related to cannabidiol, which is an antagonist at two former orphan receptors GPR18 and GPR55, that appear to be related to the cannabinoid receptors. O-1918 is used in the study of these receptors, which have been found to be targets for a number of endogenous and synthetic cannabinoid compounds, and are thought to be responsible for most of the non-CB1, non-CB2 mediated effects that have become evident in the course of cannabinoid research.

Ranbezolid (RBx7644) is an oxazolidinone antibacterial. It competitively inhibits monoamine oxidase-A (MAO-A).

HU-345 (Cannabinolquinone, CBNQ) is a drug that is able to inhibit aortic ring angiogenesis more potently than the parent compound cannabinol (CBN). It exhibits no psychoactive effects.

chemical compound

Taleranol (INN, USAN) (developmental code name P-1560), or teranol, also known as β-zearalanol, is a synthetic, nonsteroidal estrogen of the resorcylic acid lactone group related to mycoestrogens found in Fusarium spp which was never marketed. It is the β epimer of zeranol (α-zearalanol) and is a major metabolite of zeranol but with less biological activity.

experimental vaccine against COVID-19

chemical compound

5-Androstenedione, also known as androst-5-ene-3,17-dione, is a prohormone of testosterone. The World Anti-Doping Agency prohibits its use in athletes. In the United States, it is a controlled substance.

Fanetizole is a drug that has immunoregulating activity.

AFDX-384 (BIBN-161) is a drug which acts as a selective antagonist of the muscarinic acetylcholine receptors, with selectivity for the M2 and M4 subtypes. It is used mainly for mapping the distribution of M2 and M4 muscarinic receptors in the brain, and studying their involvement in the development and treatment of dementia and schizophrenia.

Phenazolam, (Clobromazolam, DM-II-90, BRN 4550445) is a benzodiazepine derivative which acts as a potent sedative and hypnotic drug. It was first invented in the early 1980s, but was never developed for medical use. It has been sold over the internet as a designer drug, first being identified in seized samples by a laboratory in Sweden in March 2016.

Silandrone (, ) (developmental code name SC-16148), also known as testosterone 17β-trimethylsilyl ether or 17β-trimethylsilyltestosterone, as well as 17β-(trimethylsiloxy)androst-4-en-3-one, is a synthetic anabolic-androgenic steroid (AAS) and an androgen ether – specifically, the 17β-trimethylsilyl ether of testosterone – which was developed by the G. D. Searle & Company in the 1960s but was never marketed. It has a very long duration of action when given via subcutaneous or intramuscular injection, as well as significantly greater potency than that of testosterone propionate. In addition, si

Medroxalol is a vasodilator beta blocker also classified as a mixed receptor blocker as it blocks both alpha and beta receptors.

Fluorolintane (also known as 2-FPPP and 2-F-DPPy) is a dissociative anesthetic drug that has been sold online as a designer drug.

5-HO-DiPT, also known as '5-hydroxy-N,N-di-iso-propyltryptamine', is a tryptamine derivative which acts as a serotonin receptor agonist. It is primarily known as a metabolite of the better known psychoactive drug 5-MeO-DiPT, but 5-HO-DiPT has also rarely been encountered as a designer drug in its own right. Tests in vitro show 5-HO-DiPT to have high serotonin 5-HT2A receptor affinity and good selectivity over the serotonin 5-HT1A receptor, while being more lipophilic than the related drug bufotenine (5-HO-DMT), which produces primarily peripheral effects.

Cymserine is a drug related to physostigmine, which acts as a reversible cholinesterase inhibitor, with moderate selectivity (15 times) for the plasma cholinesterase enzyme butyrylcholinesterase, and relatively weaker inhibition of the better-known acetylcholinesterase enzyme. This gives it a much more specific profile of effects that may be useful for treating Alzheimer's disease without producing side effects such as tremors, lacrimation, and salivation that are seen with the older nonselective cholinesterase inhibitors currently used for this application, such as donepezil.

RO5166017, or RO-5166017, is a drug developed by Hoffmann-La Roche which acts as a potent and selective agonist for the trace amine-associated receptor 1 (TAAR1), with no significant activity at other targets. It is a partial agonist or near-full agonist depending on the species.

5α-Androst-2-en-17-one, known by the nickname Delta-2, is an endogenous, naturally occurring, orally active anabolic-androgenic steroid (AAS) and a derivative of dihydrotestosterone (DHT). It is a metabolite of dehydroepiandrosterone (DHEA) in the body and is also a pheromone found in elephants and boars. 5α-Androst-2-en-17-one has been sold on the Internet as a "dietary supplement". It resembles desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol) in chemical structure and may act as an androgen prohormone.

chemical compound

Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since 2022, first being definitively identified in Sweden in January 2023. It is an analogue of etonitazene where the nitro (NO2) group has been replaced by a methyl (CH3) group. While formal studies into its pharmacology have yet to be carried out, it showed far less potency than etonitazene itself. Etomethazene has an analgesic potency around 20 times that of morphine with a relatively short duration of about 120 m

Clocental (dolcental) is a carbamate-derived sedative hypnotic.

Ro05-4082 (N-methylclonazepam, ID-690) is a benzodiazepine derivative developed in the 1970s. It has sedative and hypnotic properties, and has around the same potency as clonazepam itself. It was never introduced into clinical use. It is a structural isomer of meclonazepam (3-methylclonazepam), and similarly has been sold as a designer drug, first being identified in Sweden in 2017.

JWH-198 is a drug from the aminoalkylindole and naphthoylindole families which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-198 has a binding affinity at the CB1 receptor of 10 nM, binding around four times more tightly than the parent compound JWH-200, which has no substitution on the naphthoyl ring. It has been used mainly in molecular modelling of the cannabinoid receptors.

4-Ethylamphetamine (4-EA) is a substituted amphetamine derivative which has been sold as a designer drug. It is mainly known as a synthetic intermediate used as a building block to manufacture larger molecules, but 4-EA is closely related in chemical structure to designer drugs such as 4-methylamphetamine and 4-ethylmethcathinone, and is both a synthetic precursor and a metabolite of the 25-NB derivative 4-EA-NBOMe.